Taken together, these results show that there remain critical differences in the response to disease mitigating interventions and the pathological time courses of Scn1a‐ and Scn1b‐linked DEE, suggesting that treatment strategies developed for DS patients may not be sufficient for EIEE52 patients and alternative or adjunct treatment options should be explored. This evidence concerns the gene SCN1B and Dravet syndrome.